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An interactive website 
tracking COVID-19 
vaccine development
The past year has seen the rapid global 
spread of SARS-CoV-2—the virus 
responsible for the ongoing COVID-19 
pandemic. While non-pharmaceutical 
inter ventions have been the 
mainstay of epidemic control to date, 
vaccination is likely to constitute the 
definitive, long-term defence strategy 
against SARS-CoV-2 morbidity, 
mortality, and transmission, offering 
the best hope of a return to normal life.
The urgent need for effective 
vaccines has prompted vaccine 
developers to pivot towards COVID-19, 
resulting in rapid growth of preclinical 
candidates (appendix) and an 
accelerated vaccine development 
pipeline.1 In response to the unfolding 
pandemic and the extraordinary 
volume and pace of global vaccine 
research, we developed an online, 
interactive vaccine tracker hosted 
by the Vaccine Centre (VaC) at the 
London School of Hygiene and 
Tropical Medicine (LSHTM; London, 
UK). Launched in April 2020, this 
tracker aims to collate up-to-date 
information on all COVID-19 vaccine 
candidates from inception through to 
deployment, enabling policy makers, 
researchers, and the public to keep 
informed of the rapid developments. 
All code and underlying data for the 
tracker are freely available and are 
updated regularly through a Github 
repository.
The LSHTM VaC tracker is focused 
on presenting a comprehensive and 
up-to-date overview of the global 
vaccine landscape, provided in a user-
friendly and engaging format. The 
landscape feature is updated weekly, 
collating information on all preclinical 
and clinical candidates from the WHO 
COVID-19 vaccine landscape2 and 
the Milken Institute’s tracker,3 as well 
as information provided directly by 
developers. An interactive timeline 
displays clinical trial dates and 
locations for each candidate, providing 
users with the option to subset 
vaccines by platform and development 
phase.
To summarise key metrics of 
active and planned vaccine trials, 
the tracker includes a clinical trials 
database that captures specifications 
such as locations, dates, size, study 
design, masking, randomisation, 
and recruitment status of registered 
COVID-19 vaccine trials in humans. 
Newly registered or updated 
protocols are identified weekly 
via the US National Institutes of 
Health’s clinical trials database and 
the WHO landscape.2 For candidates 
undergoing phase 3 efficacy testing, 
clinical trial metrics are fed into an 
interactive trial map, which displays 
the global distribution of trials 
alongside the national case counts 
in each trial location (derived from 
the Johns Hopkins University real-
time COVID-19 dashboard4), helping 
place studies within their local 
epidemiological context.
As data from clinical trials started 
to become available in peer-reviewed 
journals and on preprint servers, the 
need for a single resource presenting 
results in a standardised and succinct 
format became increasingly evident. 
Accordingly, we launched a living 
review feature on Aug 24, 2020, which 
allows users to visualise and compare 
vaccine trial attributes, safety, 
immunogenicity, and efficacy data 
from each published report. The living 
review is updated through weekly 
searches of medRxiv and PubMed, 
using the terms “(coronavirus OR 
COVID OR SARS*) AND vaccin* AND 
(trial OR phase)”. Descriptive and 
quantitative data on study design, 
participant characteristics, safety, 
immunogenicity, and efficacy are 
extracted by a single reviewer 
and then verified by a second. For 
each study, we present the dosing 
regimens, randomisation and 
masking procedures, general inclusion 
criteria, and the inclusion of pregnant 
women and HIV-positive individuals. 
We report any vaccine-related 
serious adverse events, regardless 
of prevalence, and any non-serious 
adverse events with prevalence of 
25% or more in one or more study 
groups. Antibody levels at baseline 
and 28 days after the final dose (or 
the nearest available time point) are 
extracted for each vaccine dosing 
regimen. Primary outcomes of 
interest include antigen-specific IgG 
and neutralising antibodies against 
wild-type SARS-CoV-2 or pseudovirus, 
or both. Data on CD4-positive and 
CD8-positive T-cell responses and any 
T helper type 1 versus T helper type 2 
bias are reported where available. For 
phase 3 trials, we present efficacy 
against virologically confirmed 
symptomatic COVID-19, severe 
COVID-19, and asymptomatic SARS-
CoV-2 infection, stratified by age, 
ethnicity, or comorbidity status where 
available.
Finally, with an increasing number 
of candidates moving from clinical 
testing to real-world roll-out—
albeit not always after publication 
of phase 3 data—we recently 
incorporated an implementation 
feature on the LSHTM VaC tracker. 
This feature summarises information 
on vaccine storage requirements, 
manufacture projections, approval or 
licensure status, and ONE’s Vaccine 
Access Test scores.5 For each vaccine, 
we also display the number of 
countries reporting roll-out based on 
statistics compiled by Our World in 
Data.6 As such, the LSHTM VaC tracker 
summarises all stages of the COVID-19 
vaccine development pipeline, from 
preclinical development through to 
licensure and implementation.
The COVID-19 pandemic has 
spurred advances in vaccine 
development at an extraordinary 
scale, and the LSHTM VaC tracker 
provides a clear testimony of 
this progress. As of Jan 26, 2021, 
the COVID-19 vaccine landscape 
featured 291 candidates (appendix). 
Our clinical trials database includes 
156 registered studies spanning 
For the LSHTM VaC tracker see 
https://vac-lshtm.shinyapps.io/
ncov_vaccine_landscape/
For the repository of data and 
code see https://github.com/
vac-lshtm/VaC_tracker
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for public confidence and enthusiasm 
regarding vaccination for decades to 
come.
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pandemic escalates, the urgent need 
for multiple effective vaccines and 
their equitable global distribution is 
clear.
The rapid progress in COVID-19 
vaccine development is a testament 
not only to the dedication and 
innovation of research teams, but also 
to the public who have volunteered for 
clinical testing. Active or planned trials 
include more than 690 000 individuals 
across the globe, and this number will 
grow as further studies commence. 
This altruism must be matched with 
clear and transparent information 
regarding COVID-19 vaccine safety, 
efficacy, and implementation policy 
decisions in the national and global 
context. The implications of the 
ongoing vaccine roll-out extend 
beyond COVID-19 and will set the tone 
70 separate candidates, of which 
20 are currently undergoing phase 3 
efficacy testing (figure). Innovations 
in platforms,  manufacturing, 
delivery, and trial design have 
been notable, for example RNA-
based, plant-derived, and intranasal 
vaccines, and combined phase 1/2 
or 2/3 trials. 31 published reports 
spanning 18 separate candidates 
have shown encouraging safety 
and immunogenicity profiles for 
inactivated (n=5), non-replicating 
viral vector (n=4), RNA (n=3), protein 
subunit (n=4), DNA (n=1), and virus-
like particle (n=1) vaccines; and three 
published reports have confirmed the 
potential of vaccines to yield robust 
protective efficacy against COVID-19. 
We can only hope that further 
candidates follow—as the scale of the 
Figure: Status of the COVID-19 vaccine landscape
Includes vaccine candidates in phase 3 testing, use, or both as of Jan 26, 2021. AZLB=Anhui Zhifei Longcom Biopharmaceutical. nr=non-replicating. RIBSP=Research 
Institute for Biological Safety Problems. VLP=virus-like particle.
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